We used immunofluorescence staining to quantify expression of CXCR4 and CXCL12 in tissue samples from patients diagnosed with glioblastoma, with one cohort comprising samples taken prior to therapy and one with samples taken after therapy (Fig. 5). Here, CXCL12 is linked to glioblastoma.